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Abstract
Schwann cells (SCs) play a central role in peripheral nervous system physiology and in the response to axon injury. The
ability of SCs to proliferate, secrete growth factors, modulate immune response, migrate and re-myelinate
regenerating axons has been largely documented. However, there are several restrictions hindering their clinical
application, such as the difﬁculty in collection and a slow in vitro expansion. Adipose-derived stem cells (ASCs) present
good properties for peripheral nerve regenerative medicine. When exposed to speciﬁc growth factors in vitro, they
can acquire a SC-like phenotype (dASCs) expressing key SCs markers and assuming spindle-shaped morphology.
Nevertheless, the differentiated phenotype is unstable and several strategies, including pharmacological stimulation,
are being studied to improve differentiation outcomes. Cholinergic receptors are potential pharmacological targets
expressed in glial cells. Our previous work demonstrated that muscarinic cholinergic receptors, in particular
M2 subtype, are present in SCs and are able to modulate several physiological processes. In the present work,
muscarinic receptors expression was characterised and the effects mediated by M2 muscarinic receptor were
evaluated in rat dASCs. M2 receptor activation, by the preferred agonist arecaidine propargyl ester (APE), caused a
reversible arrest of dASCs cell growth, supported by the downregulation of proteins involved in the maintenance of
cell proliferation and upregulation of proteins involved in the differentiation (i.e., c-Jun and Egr-2), without affecting
cell survival. Moreover, M2 receptor activation in dASCs enhances a pronounced spindle-shaped morphology,
supported by Egr2 upregulation, and inhibits cell migration. Our data clearly demonstrate that rat dASCs express
functional muscarinic receptors, in particular M2 subtype, which is able to modulate their physiological and
morphological processes, as well as SCs differentiation. These novel ﬁndings could open new opportunities for the
development of combined cell and pharmacological therapies for peripheral nerve regeneration, harnessing the
potential of dASCs and M2 receptors.
Introduction
Peripheral nerve injuries (PNIs) derived from mechan-
ical trauma or surgical resection secondary to tumour
excision are frequent in human. Although the peripheral
nervous system (PNS) has a good regeneration capability,
several factors can inﬂuence nerve repair such as the type
and location of injury. However, nerve regeneration out-
comes are rarely satisfactory and full functional recovery
is often limited1. Following injury, neurons and Schwann
cells (SCs) change their cellular and molecular properties
in order to create a pro-regenerative environment2.
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Several studies reported that SCs played a relevant role in
peripheral regeneration. Regeneration of injured nerves
depends on SCs response to produce growth factors,
which convert their phenotype into a c-Jun-mediated
phenotype called repair SCs3. SCs support nerve regen-
eration by downregulating myelin genes, upregulating
trophic factor production, and increasing cytokine release,
all resulting in myelin clearance through a process called
myelinophagy, which is mediated by both SCs and mac-
rophages4. Finally, SCs form the Büngner’s bands which
drive regenerating axons towards their targets3.
Although SCs role is pivotal after nerve injury, they are
not sufﬁcient to support a complete and efﬁcient recovery
of peripheral functions clinically. Adipose-derived stem
cells (ASCs) may represent an interesting tool for regen-
erative medicine5,6, considering their ability to differ-
entiate into Schwann-like cells (differentiated adipose-
derived stem cells, dASCs) under appropriate condi-
tions7,8. After 18 days of differentiation with selective
growth factors, dASCs show properties similar to SCs and
they have the ability to improve neurite outgrowth both
in vitro and in rodent in vivo models1.
Glial cells express receptors for neurotransmitters (i.e.,
GABA, ATP, acetylcholine), which can modulate cell
growth and differentiation9–13. Acetylcholine (ACh)
involvement in the cross-talk between neurons and glia
during neurogenesis, as well as in the adult nervous sys-
tem, has been widely reported14,15.
Previous studies demonstrated that rat SCs express
cholinergic muscarinic receptors. In particular, the most
abundant receptor subtype is M29,16.
Muscarinic acetylcholine receptors are G-protein cou-
pled receptors and, in particular, M2 and M4 receptors
are coupled with Gi protein, which causes the inhibition
of cyclic AMP (cAMP) production and K+ channels
modulation14.
In SCs, the selective activation of M2 receptors causes a
reversible inhibition of cell proliferation, differentiating
SCs towards a promyelinating phenotype expressing
myelinating transcriptional factors such as Sox10 and
Krox20. At the same time the expression of proteins
involved in the maintenance of the undifferentiated state
(e.g., c-Jun, Notch-1, and Jagged-1)16 is suppressed.
Myelin alterations and axon degeneration have been also
observed in sciatic nerves of M2/M4 KO mice10.
dASCs, like SCs, express functional receptors for dif-
ferent neurotransmitters17–19. Previously, it has been
demonstrated that adipose mesenchymal stem cells
(ASCs) are cholinoceptive, expressing different muscari-
nic receptor subtypes, and in particular, M2 subtype20.
Recent study shows dASCs express choline acetyl-
transferase, vesicular acetylcholine transporter and
secreting ACh; they promote proliferation of myoblast21.
In the present work, we characterised the expression of
muscarinic receptors in dASCs and in particular the
effects mediated by M2 receptor activation in terms of cell
proliferation and migration. In dASCs, similarly to what
observed in SCs, M2 receptor activation caused a rever-
sible decrease of cell proliferation and the inhibition of
cell migration. Furthermore, the stimulation of M2
receptors enhanced a pronounced spindle-shaped mor-
phology acquired after growth factor induction, resem-
bling native SCs morphology. Therefore, M2 muscarinic
receptor could be a new pharmacological target to reg-
ulate important physio-pathological events aimed at
improving the recovery from of peripheral nerve injuries.
Results
Expression of stem cell markers and muscarinic receptors
ASCs express several stem cell markers such as CD29,
CD44, CD54 and CD9020,25,26. Firstly, to conﬁrm dASCs
differentiation, CD29, CD44 and CD90 expression was
evaluated by RT-PCR analysis both in ASCs and dASCs.
As expected, after selective growth factors exposure,
dASCs showed a signiﬁcantly downregulated expression
of stem cell markers (***p < 0.001; Fig. 1a). At the same
time dASCs signiﬁcantly increased the expression of
some glial markers such as S100β, Sox10, GFAP and P0
(Fig. 1b). Moreover, after differentiation, they assumed
elongated spindle-shaped morphology, similar to SCs
(Fig. 1c) and, as demonstrated by immunostaining, 70%
of the cells express SCs proteins such as GFAP and S100β
(Fig. 1d).
Muscarinic receptor expression was characterised in
dASCs by RT-PCR analysis, demonstrating that they
express the transcripts for m1, m2, m3 and m4 subtypes
(Fig. 2a). Giving the importance of M2 muscarinic
receptor activation in SCs9,10,16, M2 muscarinic receptors
expression was also investigated by western blot analysis,
indicating this receptor subtype is already expressed in
ASCs, as previously demonstrated20, and its expression is
not signiﬁcantly different in dASCs (Fig. 2b, c).
We also demonstrated that APE 100 µM (Arecaidine
Propargyl Ester) treatment, activating selectively M2
receptor, induced a signiﬁcant decrease of cAMP levels in
the cells, showing that M2 receptor in dASCs is functional
(Fig. 2d). Indeed, APE is able to signiﬁcantly decrease
cAMP levels after 2 h of treatment, but not following only
30min of exposure.
M2 receptor selective activation decreased cell growth
To investigate the downstream effects mediated by M2
muscarinic receptor activation, cells were treated with
APE up to 7 days. APE was used at the ﬁnal concentration
of 100 µM, the same concentration used previously in SCs
and in ASCs experiments10,20.
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After APE treatment, dASCs cell growth decreased sig-
niﬁcantly over 7 days in vitro (DIV, Fig. 3a). Moreover, to
further conﬁrm that the cell growth inhibition was speciﬁ-
cally mediated by M2 receptor, the M2 antagonist meth-
octramine was used. The results indicated that 10−7M
methoctramine was able to counteract APE effect (Fig. 3a).
Indeed, in the presence of the M2 antagonist, APE was not
able to decrease dASCs growth and the number of the cells
remained comparable to the untreated cells. The decrease
in cell growth was also conﬁrmed by the signiﬁcant
downregulation of genes involved in the control of the cell
cycle (i.e., pcna and cyclin D1) (Fig. 3b, c).
Fig. 1 Stem cell and glial markers expression. a Stem cell markers expression was assessed by RT-PCR. ASCs were used as positive control for stem
cell markers expression. After growth factors exposure, stemness markers, CD90, CD44 and CD29 were signiﬁcantly downregulated in dASCs (***p <
0.001). Data are represented as mean ± SEM of three independent experiments. b Glial markers expression was evaluated by RT-PCR. ASCs were used
as negative control, while nerve-derived SCs were used as positive control. After 18 days of differentiation, glial markers were upregulated in dASCs
(i.e., Sox10, S100β, GFAP and P0). c Analysis in contrast phase microscopy showed that dASCs changed their morphology compared to ASCs,
featuring the classical spindle-shaped morphology similar to SCs (scale bar: 200 µm). d Expression of S100β and GFAP in dASCs was analysed by
immunocytochemistry (scale bar: 100 µm)
Fig. 2 Muscarinic receptor subtypes expression. a dASCs, as well as undifferentiated ASCs express all muscarinic receptors transcripts, except M5.
GAPDH was used as housekeeping gene and brain lysates were used as positive controls. b Western blot showed M2 muscarinic receptor expression
in ASCs and dASCs. β-actin was used as protein reference. c Densitometric analysis did not show any particular variation of M2 protein levels after SCs
phenotype induction. Data are represented as mean ± SEM of three independent experiments and normalised against ASCs as control group.
d Levels of cyclic AMP (cAMP) in dASCs. cAMP levels decreased after 2 h of treatment with APE 100 µM compared to untreated controls (**p < 0.01)
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The decreased cell growth was reversible. Indeed, after
APE withdrawal, dASCs were able to rescue cell pro-
liferation. In absence of M2 agonist, dASCs were able to
recover their ability to proliferate, reaching levels of cell
number comparable to untreated controls (Fig. 3d).
In order to exclude the possible toxic effect of APE in
dASCs, Live-Dead Assay was performed. The analysis of
cell viability conﬁrmed that the total cell number is
decreased following APE treatment, as shown by the
signiﬁcant reduction of live cells stain (green, Fig. 3e, f).
However, the percentage of dead cells (red) was not sig-
niﬁcantly modiﬁed by the M2 agonist treatment,
demonstrating that APE 100 μM treatment is not cyto-
toxic for dASCs (Fig. 3e, f).
M2 receptor activation increased the spindle-shaped
morphology and SC-marker expression
After differentiation, dASCs present a typical spindle-
shaped morphology1,7,27. APE treatment caused a more
evident elongated morphology already after 24 h of
treatment (Fig. 4a, b). After APE treatment, the mean cell
diameter of the dASCs decreased and the length
increased. The results were graphed as Aspect Ratio, the
ratio between the cell length and diameter (Fig. 4b). This
ratio signiﬁcantly increased after 24 h of APE treatment
and progressively increased with the time of treatment.
To conﬁrm that aspect ratio increase was dependent on
M2 receptor activation, the same experiment was also
performed after 72 h of APE treatment and in presence of
M2 antagonist methoctramine (10−7M). When M2
antagonist was present, dASCs morphology was similar to
the untreated cells and the aspect ratio remained com-
parable to that of the untreated cells (Fig. 4c). Further-
more, a signiﬁcant upregulation of myelin protein P0
transcript, a classic SCs marker, corroborates these ﬁnd-
ings, suggesting improved SCs differentiation (Fig. 4d).
M2 receptor stimulation decreased proliferative related
genes and increased egr-2 protein
In order to validate that the decreased cell number was
associated with decreased cell proliferation and possible
differentiation, qRT-PCR was used to assess the gene
expression changes of some proliferation and differ-
entiation markers. As indicated in Fig. 5a, b, APE
Fig. 3 Cell growth was affected by M2 subtype selective activation. a Cell growth was analysed by MTS assay. M2 agonist treatment, APE
100 μM, was maintained from 3 to 7 days. M2 activation caused a decreased of cell growth (***p < 0.001). Cell growth was also evaluated in cultures
maintained in the presence of APE 100 μM plus M2 antagonist (10−7 M Methoctramine; Meth), which was able to counteract APE effect. b, c The
decreased cell growth was accompanied by a downregulated expression of cyclin D1 and PCNA transcripts (24 h of APE 100 μM treatment)(*p <
0.05). d Recovery of proliferative capability was assessed after 72 h of APE treatment (100 μM). APE was removed and the cell growth was analysed
until 120 h by MTS assay. dASCs were able to recover cell proliferation after APE withdrawal. The results are the mean ± SEM of three independent
experiments performed in triplicate (**p < 0.01 and ***p < 0.001). e, f The analysis of cell viability was performed after 48 h of APE treatment. There
was no signiﬁcant increase in the percentage of dead cells after APE treatment. Images were taken at 4x magniﬁcation (scale bar: 200 µm) and the
dead cells are highlighted with yellow arrows. (***p < 0.001). Data are represented as mean ± SEM of three independent experiments
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treatment was able to signiﬁcantly decrease c-jun and
notch-1 expression. Interestingly, the decreased expres-
sion of c-jun and notch-1 was accompanied by an
increased expression of egr-2, a gene associated to SCs
differentiation (Fig. 5c). These ﬁndings were also con-
ﬁrmed at the protein level. Indeed, M2 selective activation
was able to reduce the levels of c-Jun protein signiﬁcantly
after 4 h and to upregulate Egr-2 protein after 2 h of
treatment (Fig. 5d, e).
Neuregulins (NRG) are proteins expressed by axons and
involved in neuron-glia cross talk and some authors
described SCs ability to produce NRG-1 in absence of
axons28. In particular, several isoforms are produced by
alternative splicing: NRG1-1 is expressed in a proliferative
state, while NRG1-3 isoforms are expressed in myelinat-
ing state. By using RT-PCR, we demonstrated that dASCs
express NRG1-1 and NRG1-3 isoform transcripts (Fig.
6a). In accordance with MTS results, APE treatment
caused a decrease of NRG1-1 transcript expression and an
upregulation of NRG1-3, suggesting a switch between a
proliferative and a differentiated state (Fig. 6a, b). More-
over, M2 agonist treatment caused an increase of NRG
receptor expression, in particular the erbB2 subtype.
Conversely, erbB3 receptors transcript levels were not
modiﬁed by APE treatment (Fig. 6a, b).
M2 receptors selective stimulation altered cell migration
dASCs migration was analysed after 6 h by wound
healing assay. The results indicated that the presence of
M2 agonist APE negatively modulated cell migration.
Migration was also measured in presence of methoc-
tramine; M2 antagonist was able to counteract the APE
effect and migration was comparable to untreated cells
(Fig. 7a, b). After APE treatment, more stress ﬁbres
(shown by green Phalloidin staining, Fig. 7a) were present
in treated dASCs compared to controls, supporting the
decreased migration.
The CXCL12-CXCR7/4 pathway is usually implicated
in the control of cell migration and proliferation. In order
to explain the M2-mediated mechanisms responsible of
cell migration arrest, we analysed the mRNA levels of
SDF1/CXCL12 and its receptors CXCR4/CXCR7 by qRT-
PCR analysis. The results demonstrated that M2 agonist
treatment caused a signiﬁcant downregulation of the
Fig. 4 Morphological changes following M2 receptor selective activation. a Following APE treatment (24, 48 and 72 h of treatment) dASCs
appeared at lower density compared to untreated cells and presented a more elongated, spindle-shaped morphology (scale bar: 200 µm).
Representation of the measured lengths is highlighted by the yellow lines. b dASCs treated with APE 100 µM exhibit more spindle-like shape with an
increase of aspect ratio when compared to untreated cells (***p < 0.001). c To conﬁrm that modiﬁed cell morphology was the result of M2 selective
activation, the same experiment was performed in presence of 10−7 M of M2 antagonist Methoctramine plus APE 100 µM. M2 antagonist was able to
counteract APE effect. Aspect ratio in presence of antagonist was comparable to the untreated cells (***p < 0.001). Data are represented as mean ±
SEM of three independent experiments. d APE treatment upregulated P0 transcripts expression (**p < 0.01)
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Fig. 5 M2 receptor activation was able to regulate dASCs proliferation and differentiation markers. a, b Analysis by qRT-PCR demonstrated
that APE 100 µM negatively downregulated c-jun and notch-1 transcripts (*p < 0.05, **p < 0.01 and ***p < 0.001). c APE 100 µM induced an
upregulated expression of egr-2 mRNA at both 30 minutes and 1 h (***p < 0.001). d, e The transcriptional factors c-Jun and Egr-2 were also evaluated
by western blot analysis. β-tubulin was used as protein reference. The expression of Egr-2 appears signiﬁcantly upregulated after 4 h of treatment
while c-Jun was signiﬁcantly downregulated after 2 h of APE treatment (*p < 0.05). Data are represented as mean ± SEM of three independent
experiments
Fig. 6 Neuregulins (NRG) and their receptors were regulated by M2 muscarinic receptors. a Analysis by RT-PCR indicated that APE 100 µM was
able to downregulate NRG1-1 and upregulate NRG1-3 isoform transcripts. Moreover, M2 agonist treatment caused also an increase of erbB2 NRG
receptor expression while any particular variation of erbB3 expression was observed. b The graphs show the densitometric analysis of the band
normalised for the housekeeping gene GAPDH. The results are the mean ± SEM obtained from three independent experiments (*p < 0.05, **p < 0.01
and ***p < 0.001)
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expression of both chemokine transcripts and its recep-
tors after 24 h of treatment (Fig. 7c).
Discussion
dASCs derived from ASCs differentiation represent a
promising intervention to support and guide peripheral
nerve regeneration.
ACh controls neurite outgrowth and, via M2 muscarinic
receptors, SCs development10,16.
The data reported in the present work clearly
demonstrate that dASCs are cholinoceptive and that M2
receptor activation in dASCs produced similar effects to
that observed in SCs. The reversible inhibition of cell
proliferation, the improved spindle-shaped morphology
and the inhibition of cell migration, together with the
upregulated expression of SCs differentiation markers
such as Egr-2, suggest that the M2 receptor stimulation
may strengthen the dASCs spindle-like phenotype and
promote differentiation to a SC-like phenotype.
Although the PNS has regenerative capacity, conven-
tional treatments including surgical repair of the damaged
nerves, do not achieve complete functional recovery.
The development of novel strategies to enhance per-
ipheral nerve regeneration is, therefore, of great
relevance1.
Peripheral nerve regeneration is dependent on the
greater permissive environment which is likely provided
in part by SCs. These cells have a repertoire of phy-
siological roles, including protection and regulation of
nutritive exchanges with axons, myelin production and
digestion of axons and myelin debris, under patholo-
gical conditions. Moreover, SCs promote peripheral
nerve regeneration due to their ability to proliferate,
migrate and release growth factors driving axon elon-
gation29,30. Despite the relevant roles played by SCs
during peripheral nerve regeneration, their use in
clinical applications is rather limited. Although dASCs
may represent an excellent alternative to SCs, they
Fig. 7 dASCs migration was reduced following M2 receptor stimulation. a Wound healing experiments were set up to study cell migration. The
images were obtained at time 0 and after 6 h from scratch. Upper panel shows the images at phase contrast, whereas lower panels show the cells
stained with ﬂuorescent actin-speciﬁc dye (Phalloidin) at two different levels of magniﬁcation (scale bar: 200 µM). The distance of the gap between
two fronts was measured at the two-time points. M2 activation was able to reduce dASCs migration (***p < 0.001). This event was likely due to
M2 selective activation since following antagonization of this receptor with 10−7 M Methoctramine, cell migration was not modiﬁed, and migration
was similar to untreated cells. Phalloidin staining showed that more stress ﬁbres were present after APE treatment. b Graph showing quantitative
measurements of the distance travelled (µm) (t0−t6 h). c Analysis by qRT-PCR of CXCL4/7-CXCL12 transcripts. APE (100 μM) treatment induced a
downregulation of CXCL12-CXCR4/CXCR7 mRNA. These results are the mean ± SEM of three independent experiments (*p < 0.05; **p < 0.01; ***p <
0.001)
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quickly revert their phenotype when chemical stimu-
lation is withdrawn27.
Considering the effects mediated by M2 muscarinic
receptor activation in SCs10,16 and in ASCs20, it seems a
relevant tool to characterise M2 receptors activation also
in dASCs. These cells combined with novel treatments
may represent a successful strategy in the clinical treat-
ment of peripheral nerve lesions31.
Unlike other neurotransmitter receptors, in this
manuscript, we showed that M2 receptor expression did
not change following dASCs differentiation compared to
ASCs. It is known that M2 receptor is able to reduce
cAMP concentration via Gi-protein32. Our previous stu-
dies have clearly demonstrated by pharmacological
experiments and M2 knockdown that APE selectively
binds only M2 receptors10,33. APE treatment was able to
reduce cAMP concentration, supporting the functional
presence of M2 receptors on dASCs membrane.
Similar to observations in SCs, the pharmacological
activation of M2 muscarinic receptors reduced cell
growth, without inﬂuencing cell viability. This was
demonstrated by proliferation and live-dead studies, and
corroborated by the downregulation of genes involved in
the control of cell cycle (i.e., pcna and cyclinD1).
The inhibitory effect of M2 agonist on cell proliferation
was however reversible; APE withdrawal from culture
medium caused a rescue of dASCs proliferation, con-
ﬁrming that M2 activation maintained cell plasticity, as
observed in SCs and ASCs16,20.
SCs morphology depends on the physiological state of
the cells; they change their morphology in order to par-
ticipate at different physiological and pathological
events34. The chemical differentiation via growth factors
changes ASCs morphology, decreasing the cell diameter
and improving cell length, in a phenotype that resembles
native SCs.
Interestingly, M2 receptor activation caused a signiﬁcant
change in dASCs cell morphology, stimulating a more
evident spindle-like phenotype. It is possible to speculate
that these changes are a sign of occuring differentiation
events. In this manuscript, we showed that dASCs
expressed NRG1 isoforms transcript. NRG1 is an axonal
factor, that supports nerve regeneration35; SCs are also
able to produce this factor in autocrine way supporting
survival and proliferation also in the absence of axons28.
Indeed, several studies showed that SCs recapitulate a
nerve injury condition in vitro36. Moreover, NRG1 is able
to control many aspects of SCs differentiation and myeli-
nation37. It has recently been shown that withdrawal of
NRG1-1 in dASCs decreased the expression of SCs mar-
kers38, and it is able to improve SCs-like phenotype in
association with other growth factors (e.g., FGF, PDGF and
Fsk)39. We showed that M2 stimulation upregulated
NRG1-3, the isoform involved in the myelinating
phenotype, suggesting an improvement in the SC-like
phenotype. Our studies clearly demonstrated an upregu-
lation of NRG, followed by an early upregulation of Egr2/
Krox20 expression. We have previously shown that NRG
alone can increase Egr2/Krox20 expression without
M2 stimulation39, nevertheless, in this study we show that
the synergistic action of NRG and M2 agonist further
increases Egr2/Krox20 expression.
There is much evidence to indicate that SCs differ-
entiation in myelinating phenotype depends on Krox-20/
Egr2 and other promyelin transcription factors, that are
normally activated by axonal signals40. Moreover, c-Jun is
an important regulator of SCs plasticity and it is able to
inhibit myelin related genes3. It is interesting that c-Jun
and Egr-2 show a cross-antagonistic functional relation-
ship. In our studies, we demonstrated that M2 selective
activation was able to downregulate c-Jun after 2 h of
treatment. Interestingly, this downregulation was
accompanied by an upregulation of Egr-2, as described in
the literature. This result supports the hypothesis that
these cells respond in a similar way to SCs under phy-
siological conditions; moreover, it is shown that ACh, via
M2 receptor, is able to regulate their physiology, as
indicated by morphological changes related to Egr-2
upregulation.
Another important event in the injury response is SCs
migration. SCs are able to proliferate and then migrate to
the injured site to help environmental clearance and nerve
regeneration41. Other authors described that ACh sti-
mulation in the presence of calcium enhanced migratory
capacity via M1 subtypes in mesenchymal stem cells42.
Herein, we showed that APE treatment, via M2 receptor
stimulation, caused a decrease of cell migration in dASCs.
In particular, after APE treatment, cells reorganised their
cytoskeleton, showed a decreased cell migration, accom-
panied by a downregulated expression of CXCL12/SDF-1
and its receptors CXCR7 and CXCR4. This pathway is
involved in the control of SCs migration during regen-
eration43 and dASCs also express and secrete chemokines
and their receptors that modulate their migration activ-
ity44. In accordance with the observed inhibitory effect of
APE on dASCs migration, the expression levels of
CXCL12/SDF-1 and its receptors CXCR7 and CXCR4
were downregulated.
Albeit the ability of APE to selectively activate M2
receptor subtype has been largely demonstrated in our
previous works15,16,20,33, to conﬁrm APE speciﬁcity for
M2 receptor, we performed co-treatments with the spe-
ciﬁc M2 antagonist methoctramine. The results obtained
for the analyses of cell growth and cell migration, as well
as the study of dASCs morphology, demonstrated that the
presence of M2 antagonist counteracted the APE effects.
Altogether, these ﬁndings agree with reports in other
papers and raise the possibility of other neurotransmitter
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receptors (i.e. GABA and purinergic receptors) to mod-
ulate ASCs and dASCs physiological processes18,19,39. In
this scenario, neurotransmitter receptors could be
potential pharmacological targets to modulate ASCs
physiology and differentiation towards dASCs phenotype.
Although further analyses are needed to fully under-
stand the role of M2 receptor in differentiation and the
role of the other muscarinic receptor subtypes in dASCs,
our data suggest that the activation of muscarinic recep-
tors inﬂuences the physiology of the dASCs and could
potentially represent a therapeutic target for nerve
regeneration. In this context, we believe that these ﬁnd-
ings could lead to a novel strategy for nerve repair,
combining the potential of stem cell therapy together with
the pharmacological stimulation of neurotransmitters
receptors on transplanted ASCs.
Materials
Adipose-derived stem cells harvesting and culture
The experimental procedures that involved animals
were performed in accordance with the Animals (scien-
tiﬁc procedures) Act 1986. ASCs were isolated from adult
Sprague-Dawley rats as described previously7. Fat pads
were dissected and chopped using a sterile razor blade.
After, tissue was enzymatically digested for 1 h at 37 °C
using 0.15% (w/v) collagenase type I (Invitrogen, UK). A
100 µm ﬁlter was used to remove the undissociated tissue.
The solution was centrifugated at 1200 rpm for 10min,
and the stromal vascular fraction (SVF) was obtained. The
resultant SVF includes preadipocytes, endothelial cells,
macrophages, ﬁbroblasts and adipose-derived stem cells
(ASCs), which are able to adhere to plastic and proliferate
rapidly than the other cell type22. The stromal cell pellet
was plated in 75 cm2 cell culture ﬂasks in stem cell growth
medium consisting in alpha minimum essential medium
(α-MEM) supplemented with 10% (v/v) fetal bovine
serum (FBS), 2mM L-glutamine and 1% (v/v) Penicillin/
Streptomycin solution. Cultures were maintained at sub-
conﬂuent levels in a 37 °C incubator with 5% CO2.
Stem cells differentiation to Schwann-like phenotype
For differentiation to SCs phenotype, at passage 1–2
ASCs were treated with stem cell growth medium sup-
plemented with 1 mM β-mercaptoethanol for 24 h. The
next day, cells were incubated with 10ml of pre-
conditioning medium for 72 h containing 35 ng/ml all-
trans-retinoic acid at 37 °C. Following all-trans-retinoic
acid treatment, cells were washed carefully and stem cell
medium was replaced supplemented with 14 µM for-
skolin, 192 ng/ml glial growth factor-2 (GGF-2, Acorda,
UK), 5 ng/mL platelet-derived growth factor (PDGF,
Peprotech, USA), and 10 ng/ml basic ﬁbroblast growth
factor (bFGF Peprotech, USA) for 14 days23. The same
supplemented medium was used for cell maintenance.
Cells were incubated at humidiﬁed 37 °C environment
with 5% CO2. SCs cultures were obtained from sciatic
nerves of P1-P2 Sprague-Dawley rats using a previously
established protocol17,24 and used as positive controls for
SC-like differentiation.
Experimental set up and pharmacological treatments
M2 muscarinic receptor agonist, Arecaidine propargyl
ester hydrobromide (APE, Sigma-Aldrich, St. Louis, MO,
USA) was used at the ﬁnal concentration of 100 µM,
according to previous studies10,20. M2 muscarinic receptor
antagonist, methoctramine, was used at ﬁnal concentration
of 10−7M (Meth, Sigma-Aldrich, St. Louis, MO, USA). M2
muscarinic receptor antagonist was added 2 h before APE
treatment. Controls were obtained maintaining the cells in
normal growth medium. Technical and experimental tri-
plicates were performed for all experiments.
RT-PCR and quantitative real-time PCR (qPCR)
Cells were collected at the time point chosen and stored
in RNA cell protect agent (Qiagen, Manchester, UK). Total
RNA was isolated from dASCs using RNeasy Plus Mini Kit
(Qiagen, Manchester, UK), according to the manufacturer’s
protocol. Each sample was reverse-trascripted using RT2
First Strand Kit (Qiagen, Manchester, UK), according to the
manufacturer’s protocol. cDNA was used in RT-PCR and
primers and GoTaq Green Master Mix (Promega, Madison,
WI, USA) were added. For semiquantitative RT-PCR the
densitometric analysis of the bands were performed using
ImageJ software (NIH, Bethesda, MA, USA) (OD amplicon/
OD housekeeping gene). These values are expressed as
arbitrary units. Quantitative real-time PCR was performed
with RT2 SYBR Green qPCR Mastermix (Qiagen, Man-
chester, UK) using Corbett Rotor Gene 6000 real-time
cycler (Qiagen, UK). All reactions were carried out in tri-
plicate and the protocol used was: hot start for 10min at
95 °C, followed by 45 cycles of 15 s at 95 °C, annealing for
30 s at 55 °C and extension for 30 s at 72 °C. The sequences
of the primers used are reported in Table 1. Data were
normalised with housekeeping gene (18S or gapdh) and the
ΔΔCt method was used to determine the fold changes in
the gene expression, as compared to control.
Western blot
Whole-cells lysates were obtained by scraping cells from
conﬂuent 6 well-plates using RIPA Buffer (Sigma-Aldrich,
UK) supplemented with a cocktail of protease and pho-
phatase inhibitors (Thermo Scientiﬁc, Loughborough,
UK). Lysates were incubated for 30min on ice and then
centrifuged for 20 min at 14 rpm at 4 °C. Protein con-
centration was determined using Pierce™ BCA Protein
Assay Kit (Thermo Scientiﬁc, Waltham, MA, USA),
according to the manufacturer’s protocol. Sample buffer
(6 × ) was added to protein lysates and heated for 5 min at
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100 °C. Afterwards, 30 µg of the sample was loaded onto a
10% SDS (Sodium dodecyl sulfate) polyacrylamide gel and
run at 120 V using running buffer (25 mM Tris, 190mM
glycine, 0,08% (w/v) SDS). SDS-PAGE gels were trans-
ferred for 1 h onto nitrocellulose blotting membranes (GE
Healthcare Life Science, Amersham, Germany) at 80 V in
transfer buffer (25 mM Tris-base; 192 nM glycine, 20%
(v/v) methanol). After transfer, membranes were blocked
for 1 h in a Tris-buffer saline (TBS)- Tween Solution
containing 5% non-fat dry milk. Membranes were incu-
bated with the primary antibody, diluted in blocking
buffer, overnight at 4 °C. Primary antibodies used were:
Mouse anti-M2 antibody (1:500, Abcam, UK), rabbit anti-
c-Jun (1:1000, Abcam, UK), rabbit anti-Egr-2 (1:500,
ProteinTech, UK). After overnight incubation, mem-
branes were washed with TBS-Tween buffer and thus
incubated for 1 h at room temperature with secondary
antibody: anti-rabbit horseradish peroxidase (1:2000, Cell
Signaling, Hitchin, UK) or anti-mouse horseradish per-
oxidase (1:1000, Cell Signaling, Hitchin, UK) for chemi-
luminescence detection. Actin or β-tubulin was used as
protein reference (mouse anti-actin, 1:6000, (Millipore),
rabbit anti-β-tubulin (1:1000, Abcam, Cambridge, UK)).
To determine housekeeping protein, membranes were
stripped before re-blotting with another primary antibody.
Membranes were exposed to SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientiﬁc, Wal-
tham, MA, USA) for signal detection.
Immunocytochemistry
Cells were seeded into 35mm2 plates in complete
medium at the density of 2 × 104/ml.
Table 1 Primer sequences used in semiquantitative and quantitative RT-PCR analysis
Gene Forward Reverse
mAChR M1 5′-CCATGGAGTCCCTCACATCCT-3′ 5′-ATCTACCATGGGCATCTTGATCA-3’
mAChR M2 5′-GCTCCAATGATTCGACGTCA-3′ 5′-CGAAGTGGAAACTGTTGTTTTCAT-3′
mAChR M3 5′-TCCATCCTCAACTCTACCAAGCT-3′ 5′-TTGTGAGCATTTCTCTCCACATC-3′
mAChR M4 5′-CACTCTGCAATGCCACTTTCAA-3′ 5′-CTGTGCCGATGTTCCGATACT-3′
mAChR M5 5′-ACCCGCACTGAAAACAGTGACT-3′ 5′-ATCGGAACTAGGCAACACACTT-3′
CD29 5′-TGGGTCGCTGATTGGCTG-3′ 5′-CTCTTCAGTGACTGCAAAAATCG-3′
CD44 5′-TCATGTTAGAGCATCCGTGC-3′ 5′-GGGTTGTACATCATGCCTCC-3′
CD90 5′-TGAACCCAGTCATCAGCAT-3′ 5′-CAGTCGAAGGTTCTGGTTCACC-3′
cyclinD1 5′-CCCTCTGCACGCACTTGAAG-3′ 5′-GCGAGCCATGCTTAAGACTGA-3′
pcna 5′-GAAGCACCAAATCAAGAGAA-3′ 5′-TCACCCCGTCCTTTGCACAG-3′
notch1 5′-CTCACGCTGATGTCAATGCT-3′ 5′-GCAACACTTTGGCAGTCTTCA-3′
c-jun 5′-GATGGAAACGACCTTCTACGAC-3′ 5′-AGCGTATTCTGGCTATGCAGTT-3′
sox10 5′-ACTGGGAACAGCCAGTATATA-3' 5′-ACCAAACTCCTCCTTTGCCA-3'
s100B 5′-ATAGCACCTCCGTTGGACAG-3' 5′-TCGTTTGCACAGAGGACAAG-3'
gfap 5′-GCTGAACTGAACCAGCTTCGA-3' 5′-CTTGGCCACATCCATCTCCAC-3'
p0 5′-TCTTTTACCTGGCGCTACCAG-3' 5′-GTTGACCCTTGGCATAGTGGA-3'
egr2 5′-AACGGAGTGGCCGGAGAT-3′ 5′-ATGGGAGATCCAACGACCTCTT-3′
nrgI/I 5′-TCATCTTCGGCGAGATGTCTG-3' 5-‘CTCCTGGCTTTCATTTCTTTCA-3'
nrgI/III 5′-GGACCCCTGAGGTGAGAGAACA-3' 5′-CAGTCGTGGATGTCGATGTGG-3'
erbB2 5′-CGAGTGTCAGCCTCAAAACA-3' 5′-CTCATCCGGGTACTTCCAGA-3'
erbB3 5′-CTGTTTAGGCCAAGCAGAGG-3' 5′-GACTTTGTTTGCCTTCTCGC-3'
CXCR4 5′-GCCATGGCTGACTGGTACTT-3′ 5′-GATGAAGGCCAGGATGAGAA-3′
CXCR7 5′-GGCTACGACACACACTGCTA-3′ 5′-GGTCCACGCTCATGCATGCG-3′
CXCL12 5′-TGCATCAGTGACGGTAAGCCA-3′ 5′-ATCCACTTTAATTTCGGGTCAA-3′
18 S 5′-GGATCCATTGGAGGGCAAGT-3′ 5′-ACGAGCTTTTTAACTGCAGCAA-3′
Gapdh 5′-GTGCCAGCCTCGTCTCATAG-3′ 5′-TGATGGCAACAATGTCCACT-3′
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At subconﬂuence, cells were washed twice with PBS
and ﬁxed with 4% PFA (paraformaldehyde, PFA) for
20 min at room temperature (RT). Cells were incubated
with Triton-X 0,2% for 30 min at RT. Then cells were
washed twice with PBS and treated with block solution
(PBS 0.1% Triton X-100 and 10% normal donkey serum
(NGS) for 1 h at RT. The cells were incubated with anti-
rabbit-GFAP (1:100, DAKO, Glostrup, Denmark) and
anti-rabbit-S100β (1:100, DAKO, Glostrup, Denmark) at
4 °C overnight. The day after, cells were washed with
PBS three times for 10 min and they were incubated
with goat anti-rabbit IgG Alexa Flour 488-conjugated
antibody (Life Technologies, UK), diluted 1:500 in 0.1%
Triton X-100, 0,1% (w/v) BSA, 0,1% (w/v) Sodium Azide
in PBS for 1 h at RT. After, plates were washed 3 times
with PBS and slides were mounted with Vectashield
mounting medium for ﬂuorescence containing 4’-6’-
diamidino-2-phenylindole for nuclear staining (H1200,
Vector Lab, DBA, Milan, Italy). Images were taken using
a ﬂuorescence microscope (Olympus IX51, Sounthend-
on-Sea, UK) and processed with ImageJ 64 imaging
software (National Institutes of Health, NIH, Bethesda,
MD, USA).
Measurement of cAMP levels
Cells were seeded on 6-well plate at the density of
25 × 103 cells/well. When cells were at 80% conﬂuent,
they were treated with APE 100 μM. Each condition was
done in triplicate and samples from the same groups were
pooled. cAMP analyses were performed using cyclic AMP
Select ELISA kit (Cayman Chemical, MI, USA), according
to the manufacturer’s protocol. Plates were read with an
Asys UVM-340 microplate reader/spectrophotometer
(Biochrom, Cambridge, UK). Absorbance was recorded at
420 nm.
Proliferation assay
To study cell proliferation, dASCs were seeded on 24-well
plates at the density of 25 × 103 cells/well. After 24 h, cells
were treated with APE 100 μM (Sigma-Aldrich, St. Louis,
MO, USA) for 3, 5, 7 days. M2 muscarinic receptor
antagonist methoctramine (10−7M, Sigma-Aldrich, St.
Louis, MO, USA) was used 2 h before APE treatment, when
required. This method is based on a tetrazolium compound
reduction generating a colored formazan product by viable
cells; this is soluble in cell culture media. Cells were incu-
bated in 20% (v/v) CellTiter 96 AQueous One Solution Cell
Proliferation Assay (Promega, Southampton, UK), diluited
in phenol-free DMEM (Sigma-Aldrich, UK) for 90min at
37 °C in the dark. For each well, the absorbance at 490 nm
was recorded with an Asys UVM-340 microplate reader/
spectrophotometer (Biochrom, Cambridge, UK). After a
standard curve was performed, data were expressed as cell
number ± SEM of the mean.
Live dead assay
Cell viability was analysed by using LIVE/DEAD Viability/
Cytotoxicity Kit for mammalian cells (Molecular Probes,
Invitrogen, UK). Calcein-AM was used to identify live cells
(green ﬂuorescence; λ= 498 nm), conversely Eth-D1 was
used to identify dead cells (red ﬂuorescence; λ= 635 nm).
dASCs were plated in a concentration of 40 × 103 cells/well
into 12 well plates. Calcein-AM and Eth-D1 were added at a
concentration of 0.5 μl/ml and 2 μl/ml, respectively, and
cells were incubated for 30min at RT, and then washed in
PBS prior to imaging. Images were taken using ﬂuorescence
inverted microscope (Olympus IX51, Sounthend-on-Sea,
UK) and processed with ImageJ64 imaging software (NIH,
Bethesda, MD, USA) under 4x magniﬁcation.
Recovery assay
Recovery analysis was set up to demonstrate whether
inhibition of proliferation-APE induced was reversible.
The cells were treated for 72 h with APE. Then, complete
medium containing APE was removed; the cells were
washed once with sterile PBS, and fresh complete media
added. Growth analysis was assessed as described above.
For each well, the absorbance at 490 nm was recorded
with an Asys UVM-340 microplate reader/spectro-
photometer (Biochrom, Cambridge, UK). Stardard curve
was performed and the data were expressed as cell
number ± SEM of the mean.
Wound healing
Cell migration was evaluated into six-well plates in tri-
plicate for all conditions. Wound was generated with p200
tip and, to exclude possible proliferation interference,
Mitomycin C was also added to the cell culture media
(50 ng/ml, Sigma-Aldrich). The cells were photographed at
time 0 and after 6 h at 4x magniﬁcation. The space was
measured between two fronts at time 0 h (T0) and 6 h
(T6). The two values were subtracted, obtaining the cov-
ered space by the cells in the experimental time chosen.
After 6 h, cells were ﬁxed with 4% PFA in PBS (Sigma-
Aldrich, UK), permealized for 15min with 0.2% (v/v)
Triton-X in PBS (Sigma-Aldrich, UK) and stained for
20min at RT with Alexa 488-conjugated phalloidin (1:40,
Life Technologies, UK) diluted in 1% (w/v) BSA in PBS.
Images were taken using a ﬂuorescence microscope at 4x
magniﬁcation (Olympus IX51, Sounthend-on-Sea, UK)
and processed with ImageJ 64 imaging software (NIH,
Bethesda, MD, USA).
Cell morphology assessment
To determine individual cell morphology dASCs were
plated in six-well plates in triplicate at a density of 50 ×
103 cells/well. After 24 h, cells were treated with APE
100 μM (Sigma-Aldrich, St. Louis, MO, USA) or APE plus
M2 antagonist methoctramine (Meth10−7 M, Sigma-
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Aldrich, St. Louis, MO, USA). The time points chosen
were from 1 to 3 days after treatment.
Images were captured with an Olympus IX51 wide-ﬁeld
microscope at 10x magniﬁcation. Images were analysed
with IMAGE J (v1.47f; NIH, Bethesda, MD, USA) to
measure cell length (longest cell length) and width (nar-
rowest cell width). The aspect ratio was calculated as
length/width for each cell measured.
Statistical analysis
Data analysis were performed with GraphPad Prism (ver
7.0, GraphPad Software Inc, La Jolla, CA, USA). Data were
presented as the mean ± SEM. Student’s t-test or one-way
ANOVA analyses with Bonferroni post-tests were used. A
value of p < 0.05 was considered statistically signiﬁcant. (p
< 0.05 (*), p < 0.01 (**) and p < 0.001 (***)).
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